Published in Mult Scler on September 07, 2012
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLoS One (2013) 0.92
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open (2014) 0.80
Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One (2014) 0.78
No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol (2015) 0.77
Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis. Biomed Res Int (2015) 0.75
HLA class I & II alleles in multiple sclerosis patients from Puerto Rico. Bol Asoc Med P R (2013) 0.75
CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS One (2017) 0.75
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
Educating medical students in laboratory medicine: a proposed curriculum. Am J Clin Pathol (2010) 3.18
Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology (2007) 2.39
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology (2003) 2.13
Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol (2010) 2.07
The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 1.89
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses (2006) 1.67
Natural, innate improvements in multiple sclerosis disability. Mult Scler (2012) 1.50
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2012) 1.17
Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol (2013) 1.17
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother (2013) 1.07
Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler (2012) 1.07
Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int (2012) 1.06
The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology (2012) 1.05
Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain (2012) 1.03
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods (2008) 1.03
The natural history of primary progressive multiple sclerosis. Neurology (2009) 1.02
Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol (2008) 1.01
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open (2012) 1.00
Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler (2005) 0.99
Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler (2011) 0.97
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther (2012) 0.96
The incidence and prevalence of multiple sclerosis in nova scotia, Canada. Can J Neurol Sci (2013) 0.94
Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol (2006) 0.91
Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care (2012) 0.90
Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran. Diagn Microbiol Infect Dis (2007) 0.90
Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Mult Scler (2010) 0.89
MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med (2004) 0.88
Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit (2006) 0.88
Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res (2011) 0.87
During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol (2006) 0.87
Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol (2011) 0.86
Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol (2003) 0.86
Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci (2010) 0.85
The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res (2010) 0.84
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol (2014) 0.84
The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci (2008) 0.83
The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis. Mult Scler (2011) 0.83
The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiology (2012) 0.82
Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology (2013) 0.82
Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci (2008) 0.82
Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. J Immunol Methods (2012) 0.82
Retinal nerve fiber layer thickness in benign multiple sclerosis. Mult Scler (2013) 0.82
Children and adolescents adjustment to parental multiple sclerosis: a systematic review. BMC Neurol (2014) 0.82
Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology (2011) 0.81
Somatostatin preserved blood brain barrier against cytokine induced alterations: possible role in multiple sclerosis. Biochem Pharmacol (2013) 0.80
Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve (2013) 0.80
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs (2014) 0.80
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther (2004) 0.80
Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs (2014) 0.80
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open (2014) 0.80
CCSVI: hope, hype or snake oil? Can J Neurol Sci (2010) 0.79
Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol (2008) 0.79
Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients? Expert Rev Neurother (2009) 0.79
The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology (2003) 0.79
Obstetrical epidural and spinal anesthesia in multiple sclerosis. J Neurol (2013) 0.79
Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. Mult Scler (2012) 0.78
Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol (2014) 0.78
Time-Domain and Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer in MS Patients and Healthy Controls. J Ophthalmol (2012) 0.78
Sudden death due to undiagnosed primary amyloidosis. J Forensic Sci (2012) 0.78
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2013) 0.77
The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol (2007) 0.77
Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler (2004) 0.77
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int (2011) 0.77
A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res (2008) 0.77
Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler (2008) 0.77
Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Neurology (2005) 0.76
Multiple sclerosis and pregnancy: what should we be telling our patients? Neurology (2009) 0.76
What went wrong in the natalizumab trials Comment? Lancet (2006) 0.76
Adult celiac disease with acetylcholine receptor antibody positive myasthenia gravis. World J Gastroenterol (2009) 0.76
Interferons in relapsing remitting multiple sclerosis. Lancet (2003) 0.76
DMDs are an essential issue but are they the only issue in MS treatment? Can J Neurol Sci (2013) 0.75
The risks for falls and fractures in multiple sclerosis. Neurology (2012) 0.75
Where are we going with drugs to treat MS? Will cost continue to increase? Can J Neurol Sci (2010) 0.75
Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. Am J Epidemiol (2016) 0.75
In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media. J Otolaryngol Head Neck Surg (2014) 0.75
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2005) 0.75
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol (2004) 0.75
Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf (2014) 0.75
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes. J Neurol Sci (2002) 0.75
A case of choreoacanthocytosis with marked weight loss: impact of orolingual dyskinesia. Neurol India (2006) 0.75